Montefiore Medical Center Lobbying Disclosure: Bronx Hospital Spends $110K in First Quarter

Why It Matters

Montefiore Medical Center, the Bronx-based safety-net health system, serves a patient population heavily dependent on government programs like Medicare and Medicaid, which reimburse at lower rates than private insurance. Federal Medicaid policy changes pose a direct threat to the hospital's financial stability. In early 2026, New York state officials estimated that H.R. 1, the "One Big Beautiful Bill Act," could result in federal funding losses exceeding $13.5 billion across the state. For Montefiore specifically, the hospital posted a $73 million quarterly loss as federal aid declined. The hospital's consistent lobbying activity—now in its third year—suggests ongoing efforts to address federal healthcare reimbursement policy.

By the Numbers: Montefiore Medical Center Lobbying Disclosure Spending

Montefiore filed a congressional lobbying disclosure for the first quarter of 2026, reporting $110,000 in spending through its outside firm. Unlike prior disclosures, the filing lists no specific issues or legislation, leaving the hospital's current federal priorities opaque.
The hospital has maintained a steady lobbying presence since 2024. The hospital has retained Welsh Rose LLC across nine filings spanning first quarter 2024 through first quarter 2026, totaling $990,000 in disclosed spending. The first quarter 2026 filing of $110,000 is consistent with the hospital's quarterly rate and represents no change from prior quarters.

Welsh Rose LLC deployed two lobbyists on this engagement:

  • Kate Rose, who served as a Health Legislative Assistant for Sen. John D. Rockefeller, IV (D-WV) and previously as a Staff Assistant for Rep. Allyson Y. Schwartz (D-PA). She holds a Master of Public Health in Health Policy from George Washington University.
  • Kristin Welsh, who served as a Health Policy Adviser on the Senate Finance Committee during the 114th Congress.

Both lobbyists have remained consistent throughout Montefiore's engagement with the firm. There is no indication of new hires or changes to the lobbying team this quarter.

The Agenda

The filing lists no specific issues or legislation, a departure from prior quarters. This represents a significant change in disclosure practice.

In earlier filings, Montefiore's lobbying agenda covered:

  • Medicare and Medicaid reimbursement policy, including site-neutral payment policy
  • Exchange eligibility and enrollment policy
  • Drug pricing and NIH funding
  • School-based health center funding
  • Congressionally directed funding
  • FEMA reimbursement (added in Q4 2025)
  • H.R. 1, the One Big Beautiful Bill Act—monitored through enactment and into implementation

The last quarter 2025 filing](https://app.legis1.com/lda-filings/detail?id=2054777#summary) specifically noted monitoring H.R. 1's implementation, suggesting a shift from legislative influence to regulatory tracking. Whether that posture continues into 2026 is unclear from the current disclosure.

Broader Contex

Montefiore operates in an environment of significant federal and congressional pressure. Crain's New York Business reported that the hospital is bracing for funding losses tied to H.R. 1, which could cause Medicaid enrollees to lose coverage—shifting uncompensated care costs onto hospitals. The New York State Association of Counties warned that federal Medicaid cuts would "cripple troubled health care centers."

Montefiore also faces congressional scrutiny unrelated to reimbursement. In January 2026, Rep. Jason Smith (R-MO), chair of the House Ways and Means Committee, announced an investigation into Montefiore and the University of Chicago Medical Center over allegations that wealthy foreign nationals were allowed to pay their way ahead of American citizens on organ transplant waiting lists. Smith raised questions about the hospital's tax-exempt status in connection with the allegations. Montefiore has not been found to have engaged in misconduct; the investigation was announced as an inquiry.

On a positive note, Montefiore's leadership testified before Congress in a hearing titled "Reducing Health Care Costs: Eliminating Excess Health Care Spending and Improving Quality and Value for Patients." The hospital's president and CEO described Montefiore's experience as New York State's only Pioneer Accountable Care Organization and noted the system generated over $73 million in savings to Medicare over five years through the program. That testimony positions the hospital as an advocate for value-based payment structures.

In November 2025, Rep. Mike Lawler (R-NY) held a press conference with Montefiore Nyack Hospital to announce the reintroduction of the IVF Access and Affordability Act, which would provide up to a $40,000 federal tax credit for fertility treatments.

Montefiore also announced a restructuring plan that drew criticism from the New York State Nurses Association, which said the plan could eliminate hospital beds and certain surgical and palliative care services at Montefiore Moses in the Bronx. Despite those pressures, the system is pursuing an expansion that would add four hospitals across Westchester and the Hudson Valley.

Competitive Landscape

Montefiore is not alone in lobbying on healthcare reimbursement and federal policy. Welsh Rose LLC, the firm representing Montefiore, also lobbies on behalf of other major healthcare organizations with similar policy interests. Mayo Clinic spent $240,000 with Welsh Rose LLC in 2025 on Medicare and Medicaid issues. The Federation of American Hospitals spent $150,000 in 2025 lobbying on Medicare/Medicaid policy and H.R. 1. Hackensack (N.J.) Meridian Health Inc. spent $130,000 on similar healthcare payment issues, also lobbying on H.R. 1 and the Resident Physician Shortage Act. This clustering of healthcare organization lobbying reflects industry-wide concern about federal payment policy changes.

The Bottom Line

Montefiore's first quarter lobbying disclosure is notable as much for what it omits as what it contains. The blank issues field offers no window into the hospital's current federal priorities, even as it faces a convergence of financial losses, congressional scrutiny, Medicaid policy changes, and an ongoing restructuring. The hospital's consistent quarterly spend and unchanged lobbying team suggest continuity of strategy, but the absence of disclosed specifics makes it difficult to assess where that strategy is currently directed.